文献速递临床试验与 GCP流行病学与生物统计

OACART研究方案:氯吡格雷为基础抗血小板治疗与阿司匹林联合低剂量利伐沙班在动脉粥样硬化性心血管疾病中的非劣效性随机对照试验

Optimal strategy for treatment of atherosclerotic cardiovascular disease-comparison of clopidogrel-based antiplatelet agent treatment versus aspirin plus low dose rivaroxaban therapy (OACART study): a study protocol for a multicenter, open-label, randomized, non-inferiority trial.
PubMed 文献 · Trials · 2026-07-30

OACART试验是一项多中心、开放标签、随机、非劣效性研究,计划在韩国招募2758例慢性稳定性高危冠心病或冠心病合并外周动脉疾病患者,1:1随机接受氯吡格雷为基础抗血小板治疗(CAPT)或阿司匹林联合低剂量利伐沙班双通路抑制(DPI),主要评估36个月时净临床结局的非劣效性。

要点

  • 比较CAPT与DPI在慢性稳定性高危CAD或CAD+PAD患者中的疗效与安全性。
  • 主要终点为36个月净临床结局,包括全因死亡、心肌梗死、卒中、缺血驱动血运重建等。

核心结论

  • OACART试验旨在为稳定性高危动脉粥样硬化患者提供最佳抗血栓治疗策略。

研究设计与样本

  • 多中心、开放标签、随机、非劣效性试验,计划在韩国招募2758例慢性稳定性高危冠心病或冠心病合并外周动脉疾病患者。
  • 患者按1:1比例随机接受氯吡格雷为基础抗血小板治疗(CAPT)或阿司匹林联合低剂量利伐沙班双通路抑制(DPI)。
  • 试验针对36个月时的主要和次要疗效终点进行非劣效性检验。

关键数值与推荐

  • 主要终点为36个月净临床结局,包括全因死亡、任何心肌梗死、任何卒中、任何缺血驱动的血运重建(CAD或PAD)、急性肢体缺血、任何大或小截肢、任何急性血栓栓塞以及ISTH大出血。

临床怎么用

  • 若CAPT非劣效于DPI,可为高出血风险或不能耐受利伐沙班的患者提供替代抗血栓策略。

局限性

  • 开放标签设计可能引入偏倚。
  • 结果尚未报告,目前仅为研究方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent studies have demonstrated the superior benefits of clopidogrel compared to aspirin in reducing mortality, myocardial infarction, stroke, and hospitalization in chronic stable patients with coronary stenting. Furthermore, dual pathway inhibition by combining low-dose rivaroxaban with aspirin (DPI) has shown superior effects in preventing cardiovascular death, myocardial infarction, and stroke in stable atherosclerotic patients. However, no studies have directly compared these treatment strategies in the same population. This randomized controlled trial aims to compare clopidogrel-based antiplatelet therapy with or without aspirin (CAPT) to DPI in a 1:1 ratio in patients with high-risk coronary artery disease (CAD) or in patients with both CAD and peripheral artery disease (PAD). METHODS: Optimal strategy for treatment of Atherosclerotic cardiovascular disease-comparison of Clopidogrel-based Antiplatelet agent treatment versus aspirin plus low dose Rivaroxaban Therapy (OACART) trial is a randomized multi-center study comparing the performance of the maintaining CAPT or DPI in a 1:1 ratio. The trial is powered for the non-inferiority of the CAPT in patients with chronic stable high-risk CAD or CAD+PAD to DPI with respect to the primary and secondary efficacy endpoints at 36 months. RESULTS: Between November 2023 and April 2026, we will recruit 2758 participants from multi-center in Korea, and we will examine the net clinical outcome, including all-cause death, any myocardial infarction, any stroke, any ischemia-driven revascularization (CAD or PAD), acute limb ischemia, any major or minor amputations, any acute thromboembolism, and International Society on Thrombosis and Haemostasis major bleeding at 36 months after study enrollment. CONCLUSIONS: OACART trial will provide the optimal antithrombotic treatment strategy for patients with stable high-risk atherosclerosis. TRIAL REGISTRATION: Clinical Research Information Service (CRIS) of Republic of Korea, KCT0008458, registered on May 22, 2023. https://cris.nih.go.kr/cris/search/detailSearch.do?seq=28968&search_page=L.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kwun, Yoon, Jeon, et al. Optimal strategy for treatment of atherosclerotic cardiovascular disease-comparison of clopidogrel-based antiplatelet agent treatment versus aspirin plus low dose rivaroxaban therapy (OACART study): a study protocol for a multicenter, open-label, randomized, non-inferiority trial. Trials. 2026. PMID: 42934720. doi:10.1186/s13063-026-09899-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。